每日阿司匹林使用与非酒精性脂肪性肝病纤维化进展风险降低相关
前瞻性队列纳入361例活检确诊的非酒精性脂肪性肝病(NAFLD)成人,2006至2015年每3至12个月随访。每日阿司匹林使用与脂肪性肝炎(NASH)和纤维化患病率较低相关,并与进展至晚期纤维化风险降低相关,且呈持续时间依赖性;非阿司匹林非甾体抗炎药(NSAID)使用与晚期纤维化风险无关。
要点
- 每日阿司匹林使用与NASH患病几率较低相关(校正OR 0.68,95%CI 0.37-0.89)。
- 每日阿司匹林使用与纤维化患病几率较低相关(校正OR 0.54,95%CI 0.31-0.82)。
- 基线F0-F2纤维化者中,每日阿司匹林使用与进展至晚期纤维化风险较低相关(aHR 0.63,95%CI 0.43-0.85)。
核心结论
- 在活检证实的NAFLD患者的前瞻性研究中,每日阿司匹林使用与NAFLD和NASH组织学特征较轻及随时间进展至晚期纤维化风险较低相关。
研究设计与样本
- 前瞻性队列研究,纳入361例活检确诊的NAFLD成人,2006年至2015年每3至12个月随访,基线肝活检由盲法病理学家进行组织学分析。
主要发现
- 入组时151例每日使用阿司匹林;与不规律使用相比,每日阿司匹林使用与NASH患病几率较低相关(校正OR 0.68,95%CI 0.37-0.89)及纤维化患病几率较低相关(校正OR 0.54,95%CI 0.31-0.82)。
- 基线F0-F2纤维化者(n=317)中,86例在3692人年间进展为晚期纤维化;每日阿司匹林使用者进展至晚期纤维化风险显著低于不规律使用者(aHR 0.63,95%CI 0.43-0.85)。
- 该关系呈持续时间依赖性(校正P趋势=0.026),使用阿司匹林至少4年或以上获益最大(aHR 0.50,95%CI 0.35-0.73)。
- 非阿司匹林NSAID使用与晚期纤维化风险无关(aHR 0.93,95%CI 0.81-1.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There are few data from prospective studies on the effects of aspirin on fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). METHODS: We performed a prospective cohort study of 361 adults with biopsy-confirmed NAFLD, from 2006 through 2015, examined every 3-12 months for incident advanced fibrosis defined using serial measurements of validated indices (the Fibrosis-4, NAFLD fibrosis score, and aspartate aminotransferase to platelet ratio indices). Histologic analyses of liver biopsies collected at baseline were performed by a blinded pathologist. Information collected at baseline and at each examination included frequency and duration of aspirin and nonsteroidal anti-inflammatory drug (NSAID) use. Using multivariable-adjusted logistic regression, we estimated the association of aspirin use with prevalent steatohepatitis (NASH) and fibrosis. Using multivariable-adjusted Cox proportional hazards modeling, we estimated the association between aspirin use and risk for fibrosis progression. RESULTS: At enrollment, 151 subjects used aspirin daily. Compared with non-regular use, daily aspirin use was associated with significantly lower odds of NASH (adjusted odds ratio, 0.68; 95% CI, 0.37-0.89) and fibrosis (adjusted odds ratio, 0.54; 95% CI, 0.31-0.82). Among individuals with baseline F0-F2 fibrosis (n = 317), 86 developed advanced fibrosis over 3692 person-years. Daily aspirin users had significantly lower risk for developing incident advanced fibrosis vs non-regular users (adjusted hazard ratio [aHR], 0.63; 95% CI, 0.43-0.85). This relationship appeared to be duration dependent (adjusted P trend=.026), with the greatest benefit found with at least 4 years or more of aspirin use (aHR, 0.50; 95% CI, 0.35-0.73). Conversely, use of nonaspirin NSAIDs was not associated with risk for advanced fibrosis (aHR, 0.93; 95% CI, 0.81-1.05). CONCLUSIONS: In a prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and lower risk for progression to advanced fibrosis with time.
引用
- Simon TG, Henson J, Osganian S, et al. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019. PMID: 31077838. doi:10.1016/j.cgh.2019.04.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。